Academia–industry partnerships in drug discovery
Authors:
- Debbie TaylorDTDebbie Taylor
- Catherine KettleboroughCKCatherine Kettleborough
- Justin BryansJBJustin Bryans
- Roberto SolariRSRoberto Solari
- 6 June 2006
- journal article
- Published by Informa Healthcare in Expert Opinion on Drug Discovery
- Vol. 1 (1) , 1-6
Abstract
The movement of ideas and innovation from academia into the world of business has a long and fruitful history. Ironically, it might be argued that the recent pressure put on universities and basic research organisations to protect and exploit their intellectual property has, in many ways, created a less conducive environment to successful commercialisation than existed 30 years ago. This movement has been concurrent with the drift of the Pharmaceutical industry towards a more risk-averse R&D strategy in which it has increasingly concentrated its resources on a reductionist drug discovery process and later stage clinical development. In effect, these two strategies have created a discontinuity between academic scientific output and industry at a time when academia as a source of innovation is perhaps more important to industry than ever.Keywords
This publication has 10 references indexed in Scilit:
- 2005 approvals: Safety firstNature Reviews Drug Discovery, 2006
- Finding improved medicines: the role of academic–industrial collaborationNature Reviews Drug Discovery, 2005
- Cancer drug discovery through collaborationNature Reviews Drug Discovery, 2005
- The origins of new drugsNature Biotechnology, 2005
- Drug Discovery2005
- Prospects for productivityNature Reviews Drug Discovery, 2004
- The $800 Million Pill2004
- Invited Perspective: High-Throughput Screening in Academia: The Harvard ExperienceSLAS Discovery, 2003
- Invited Perspective: Screening in Academe: A Perspective on Implementation of University-Based Small Molecule ScreeningSLAS Discovery, 2003
- The druggable genomeNature Reviews Drug Discovery, 2002